Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
Indian J Cancer
; 2012 Apr-June; 49(2): 202-208
Article
Dans En
| IMSEAR
| ID: sea-144573
ABSTRACT
Purpose:
Gemcitabine in low-dose prolonged infusion is a treatment with documented activity against a variety of tumors. The present study was conducted to evaluate the efficacy and safety of the combination of gemcitabine at a low-dose prolonged infusion in comparison with standard dose gemcitabine with carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Materials andMethods:
Sixty chemonaive patients with stage IIIB or IV NSCLC were included. Patients were randomly assigned 11 to receive 350mg/m 2 gemcitabine in a 6-h infusion on days 1 and 8 and carboplatin area under the serum concentration time curve (AUC) 5 on day 1 versus gemcitabine 1000mg/m 2 on days 1 and 8 and carboplatin AUC 5 on day 1 (3-week cycle both). A total of 118 chemotherapy cycles, with a median of 4 cycles per patient (range 2-6), and 134 chemotherapy cycles, with a median of 4.47 cycles per patient (range 3-6) were administered in standard and low infusional dose arm, respectively.Results:
Among patients in the standard arm, 40% had overall response rate (ORR), 33.3% had stable disease and 26.6% had progressive disease, while in low-dose infusional arm, 36.6% had ORR, 36.3% had stable disease and 26.6% had progressive disease (P = 0.992). Median progression-free survival was 5.5 months and 5.4 months, median overall survival was 9.7 months and 10.7 months, and 1-year survival was 33.7% and 36.6% in standard arm and low-dose infusion arm, respectively. Grade 3/4 toxicity was rare.Conclusion:
In NSCLC, gemcitabine low-dose prolonged infusion with carboplatin has low toxicity, especially thrombocytopenia, and has an activity comparable with gemcitabine given in higher dose in standard infusion.
Texte intégral:
1
Indice:
IMSEAR
Sujet Principal:
Humains
/
Protocoles de polychimiothérapie antinéoplasique
/
Carboplatine
/
Systèmes de délivrance de médicaments
/
Carcinome pulmonaire non à petites cellules
/
Dosage
/
Calcul des posologies
/
Antimétabolites antinéoplasiques
langue:
En
Texte intégral:
Indian J Cancer
Année:
2012
Type:
Article